Dss announces licensing of impact biomedical's linebacker portfolio to prophase labs

Rochester, n.y., july 21, 2022 (globe newswire) -- dss, inc. (nyse american: dss), a multinational company operating businesses within nine divisions and strategically acquiring and developing assets to enrich the value of its shareholders through calculated ipo spinoffs and a parametric share distribution strategy, today announced global biolife, inc. (“global biolife”), a subsidiary of the company's wholly owned subsidiary impact biomedical, inc. (“impact biomedical”), executed a license agreement with prophase biopharma, inc. (“pbio”), a subsidiary of prophase labs, inc. (nasdaq: prph), a rapidly growing and diversified diagnostics, genomics and biotech company, for global biolife's linebacker portfolio (lb-1 and lb-2), two patented small molecule pim kinase inhibitors with significant potential across multiple therapeutic indications.
DSS Ratings Summary
DSS Quant Ranking